The first regulated therapy to emerge from the recent explosion of microbiome research is one step closer. And the company developing it, Seres Health, is stepping toward the first microbiome startup IPO, Xconomy has learned.
The Cambridge, MA startup announced today that its lead product, made from a mix of bacterial spores, has effectively cured 29 of 30 patients who suffered from recurring infection of the potentially deadly bacterium Clostridium difficile, or C. diff.
Help employers find you! Check out all the jobs and post your resume.
